• Je něco špatně v tomto záznamu ?

Oral vinorelbine plus cisplatin as first-line chemotherapy in nonsquamous non-small-cell lung cancer: final results of an International randomized phase II study (NAVotrial 01)

J. Bennouna, L. Havel, M. Krzakowski, J. Kollmeier, R. Gervais, E. Dansin, M. Serke, A. Favaretto, A. Szczesna, M. Cobo, L. Ciuffreda, J. Jassem, M. Nicolini, R. Ramlau, D. Amoroso, B. Melotti, T. Almodovar, M. Riggi, NR. Caux, N. Vaissière, EH. Tan,

. 2014 ; 15 (4) : 258-65.

Jazyk angličtina Země Spojené státy americké

Typ dokumentu klinické zkoušky, fáze II, časopisecké články, multicentrická studie, randomizované kontrolované studie, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc15023312

BACKGROUND: The combination of oral vinorelbine plus cisplatin has been studied in numerous trials as first-line treatment of patients with non-small cell lung cancer (NSCLC) regardless of histologic subtype. NAVoTrial 01 is the first study that explores this combination specifically in nonsquamous (NS) NSCLC by assessing the feasibility of this doublet (ratio 1:2) in an investigational approach. A reference arm with pemetrexed plus cisplatin was included. Maintenance therapy with single-agent therapy after 4 cycles of combination therapy was included in the study schedules because it reflected a trend in first-line treatment of NSCLC. PATIENTS AND METHODS: Stage IIIB/IV untreated/relapsed patients with NS NSCLC received a 3-week cycle of pemetrexed 500 mg/m(2) and cisplatin 75 mg/m(2) on day 1 (arm A) or oral vinorelbine 80 mg/m(2) on days 1 and 8 (first cycle 60 mg/m(2)) and cisplatin 80 mg/m(2) on day 1 (arm B). After 4 cycles, patients without disease progression received single-agent maintenance treatment with pemetrexed or oral vinorelbine. RESULTS: Overall, 153 patients were randomized (arm A/arm B: 51/102). Disease control rate (%) for arm A was 76.5 (95% confidence interval [CI], 62.5-87.2) and for arm B it was 75.0 (95% CI, 65.3-83.1), Response rates for arm A were 31.4% (95% CI, 19.1-45.9) and for arm B were 24.0% (95% CI, 16.0-33.6). Median progression-free survival for arm A was 4.3 months (95% CI, 3.8-5.6) and for arm B it was 4.2 months (95% CI, 3.6-4.7). Median survival for arm A was 10.8 months (95% CI, 7.0-16.4) and for arm B it was 10.2 months (95% CI, 7.8-11.9). Main grade 3/4 hematologic toxicities were neutropenia 18.3% (arm A) and 44.0% (arm B), whereas febrile neutropenia was reported in 2% of patients in each arm. CONCLUSION: Oral vinorelbine and cisplatin had an efficacy in line with that achieved with a standard treatment such as pemetrexed and cisplatin, coupled with an acceptable safety profile.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc15023312
003      
CZ-PrNML
005      
20150729110554.0
007      
ta
008      
150709s2014 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.cllc.2014.04.007 $2 doi
035    __
$a (PubMed)24954228
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Bennouna, Jaafar $u Institut de Cancérologie de l'Ouest, Nantes, France.
245    10
$a Oral vinorelbine plus cisplatin as first-line chemotherapy in nonsquamous non-small-cell lung cancer: final results of an International randomized phase II study (NAVotrial 01) / $c J. Bennouna, L. Havel, M. Krzakowski, J. Kollmeier, R. Gervais, E. Dansin, M. Serke, A. Favaretto, A. Szczesna, M. Cobo, L. Ciuffreda, J. Jassem, M. Nicolini, R. Ramlau, D. Amoroso, B. Melotti, T. Almodovar, M. Riggi, NR. Caux, N. Vaissière, EH. Tan,
520    9_
$a BACKGROUND: The combination of oral vinorelbine plus cisplatin has been studied in numerous trials as first-line treatment of patients with non-small cell lung cancer (NSCLC) regardless of histologic subtype. NAVoTrial 01 is the first study that explores this combination specifically in nonsquamous (NS) NSCLC by assessing the feasibility of this doublet (ratio 1:2) in an investigational approach. A reference arm with pemetrexed plus cisplatin was included. Maintenance therapy with single-agent therapy after 4 cycles of combination therapy was included in the study schedules because it reflected a trend in first-line treatment of NSCLC. PATIENTS AND METHODS: Stage IIIB/IV untreated/relapsed patients with NS NSCLC received a 3-week cycle of pemetrexed 500 mg/m(2) and cisplatin 75 mg/m(2) on day 1 (arm A) or oral vinorelbine 80 mg/m(2) on days 1 and 8 (first cycle 60 mg/m(2)) and cisplatin 80 mg/m(2) on day 1 (arm B). After 4 cycles, patients without disease progression received single-agent maintenance treatment with pemetrexed or oral vinorelbine. RESULTS: Overall, 153 patients were randomized (arm A/arm B: 51/102). Disease control rate (%) for arm A was 76.5 (95% confidence interval [CI], 62.5-87.2) and for arm B it was 75.0 (95% CI, 65.3-83.1), Response rates for arm A were 31.4% (95% CI, 19.1-45.9) and for arm B were 24.0% (95% CI, 16.0-33.6). Median progression-free survival for arm A was 4.3 months (95% CI, 3.8-5.6) and for arm B it was 4.2 months (95% CI, 3.6-4.7). Median survival for arm A was 10.8 months (95% CI, 7.0-16.4) and for arm B it was 10.2 months (95% CI, 7.8-11.9). Main grade 3/4 hematologic toxicities were neutropenia 18.3% (arm A) and 44.0% (arm B), whereas febrile neutropenia was reported in 2% of patients in each arm. CONCLUSION: Oral vinorelbine and cisplatin had an efficacy in line with that achieved with a standard treatment such as pemetrexed and cisplatin, coupled with an acceptable safety profile.
650    _2
$a aplikace orální $7 D000284
650    _2
$a senioři $7 D000368
650    _2
$a protokoly antitumorózní kombinované chemoterapie $x terapeutické užití $7 D000971
650    _2
$a nemalobuněčný karcinom plic $x farmakoterapie $x mortalita $7 D002289
650    _2
$a cisplatina $x aplikace a dávkování $x škodlivé účinky $7 D002945
650    _2
$a progrese nemoci $7 D018450
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a glutamáty $x aplikace a dávkování $x škodlivé účinky $7 D005971
650    _2
$a guanin $x aplikace a dávkování $x škodlivé účinky $x analogy a deriváty $7 D006147
650    _2
$a lidé $7 D006801
650    _2
$a mezinárodní spolupráce $7 D007391
650    _2
$a nádory plic $x farmakoterapie $x mortalita $7 D008175
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a staging nádorů $7 D009367
650    _2
$a neutropenie $x etiologie $7 D009503
650    _2
$a analýza přežití $7 D016019
650    _2
$a vinblastin $x aplikace a dávkování $x škodlivé účinky $x analogy a deriváty $7 D014747
655    _2
$a klinické zkoušky, fáze II $7 D017427
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Havel, Libor $u Department of Pneumology and Thoracic Surgery, University Hospital Bulovka, Prague, Czech Republic.
700    1_
$a Krzakowski, Maciej $u Maria Sklodowska-Curie Oncology Centre, Institute of Oncology, Chest Oncology, Warsaw, Poland.
700    1_
$a Kollmeier, Jens $u Department of Pneumology, Lungenklinik Heckeshorn, Helios-Klinikum Emil von Behring, Berlin, Germany.
700    1_
$a Gervais, Radj $u Department of Oncology, Centre François Baclesse, Caen, France.
700    1_
$a Dansin, Eric $u Department of Oncology, Centre Oscar Lambret, Lille, France.
700    1_
$a Serke, Monika $u Department of Pneumology III, Lungenklinik Hemer, Hemer, Germany.
700    1_
$a Favaretto, Adolfo $u Veneto Institute of Oncology IOV-IRCCS, Second Medical Oncology Unit, Padova, Italy.
700    1_
$a Szczesna, Aleksandra $u Department of Oncology, Mazowieckie Centrum ChorobPluciGruzlicy, Otwocku, Poland.
700    1_
$a Cobo, Manuel $u Department of Medical Oncology, Hospital Clinico Carlos Haya, Malaga, Spain.
700    1_
$a Ciuffreda, Libero $u Ospedale Molinette, Oncologia Medica, Torino, Italy.
700    1_
$a Jassem, Jacek $u Department of Oncology and Radiotherapy, Medical University of Gdansk, Gdansk, Poland.
700    1_
$a Nicolini, Mario $u Ospedale Cervesi, U.O.S. di Oncologia, Cattolica, Italy.
700    1_
$a Ramlau, Rodryg $u Department of Oncology, Wielkopolskie Centrum Pulmonologii Torakochirurgii, Poznan, Poland.
700    1_
$a Amoroso, Domenico $u Ospedale Versilia, UOC Oncologia Medica, Lido di Camaiore, Italy. $7 gn_A_00005723
700    1_
$a Melotti, Barbara $u Department of Medical Oncology, S Orsola-Malpighi Hospital, Bologna, Italy.
700    1_
$a Almodovar, Teresa $u Department of Oncology, Instituto Portugues De Oncologia, Porto, Portugal. $7 gn_A_00004644
700    1_
$a Riggi, Marcello $u Department of Oncology, Institut de Recherche Pierre Fabre, Paris, France. Electronic address: marcello.riggi@pierre-fabre.com.
700    1_
$a Caux, Noël-Raphaël $u Department of Oncology, Institut de Recherche Pierre Fabre, Paris, France.
700    1_
$a Vaissière, Nathalie $u Department of Oncology, Institut de Recherche Pierre Fabre, Paris, France.
700    1_
$a Tan, Eng-Huat $u Department of Medical Oncology, National Cancer Centre, Singapore.
773    0_
$w MED00006451 $t Clinical lung cancer $x 1938-0690 $g Roč. 15, č. 4 (2014), s. 258-65
856    41
$u https://pubmed.ncbi.nlm.nih.gov/24954228 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20150709 $b ABA008
991    __
$a 20150729110641 $b ABA008
999    __
$a ok $b bmc $g 1083650 $s 906305
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2014 $b 15 $c 4 $d 258-65 $i 1938-0690 $m Clinical lung cancer $n Clin Lung Cancer $x MED00006451
LZP    __
$a Pubmed-20150709

Najít záznam

Citační ukazatele

Možnosti archivace